Sarepta-partnered Hansa touts new phase 2 data of one-trick pony immunological treatment

Hansa Biopharma is hailing new phase 2 data of its all-in-one transplantation treatment imlifidase as evidence of the med’s superiority to standard of care for patients with antibody-mediated rejection.